Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial

Charles Craddock, Aimee E. Houlton, Paul Ferguson, Manoj Raghavan, Sonia Fox, Louise Dudley, Lynn Swun Quek, Jamie D. Cavenagh, Michael Dennis, Keith Wheatley, Paresh Vyas, Mary Frances McMullin, Srinivas P Pillai, Richard Kelly, Shamyla Siddique, Keith Wheatley, Paresh Vyas

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)1065
JournalBlood
Volume128
Issue number22
Publication statusPublished - 30 Nov 2016

Cite this

Craddock, C., Houlton, A. E., Ferguson, P., Raghavan, M., Fox, S., Dudley, L., Quek, L. S., Cavenagh, J. D., Dennis, M., Wheatley, K., Vyas, P., McMullin, M. F., Pillai, S. P., Kelly, R., Siddique, S., Wheatley, K., & Vyas, P. (2016). Vorinostat Does Not Improve Outcome in Patients with Acute Myeloid Leukemia and High Risk Myelodysplasia Treated with Azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial. Blood, 128(22), 1065. http://www.bloodjournal.org/content/128/22/1065